| JNJ |
Report |
Adjusted EPS |
BEAT |
pred ~$2.91 vs. cons $2.86 |
MEDIUM |
| JNJ |
Report |
Total Revenue |
BEAT |
pred ~$25.6B vs. cons $25.3B |
MEDIUM |
| JNJ |
Report |
Innovative Medicine Segment Sales |
BEAT |
pred ~$16.35B vs. cons $16.1B |
MEDIUM |
| JNJ |
Guide |
FY2026 Operational Sales Guidance |
BETTER |
guide ~$100.6B vs. cons $100.2B (FY2026) |
MEDIUM |
| JNJ |
Guide |
FY2026 Adjusted Operational EPS Guidance |
BETTER |
guide ~$11.55 vs. cons $11.42 (FY2026) |
MEDIUM |
| JNJ |
Guide |
FY2026 Adjusted Pretax Operating Margin Expansion |
UNCHANGED |
guide ~+55bps vs. cons +50bps (FY2026) |
LOW |
| JNJ |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.9% |
— |
MEDIUM |
| JNJ |
Return |
5-day cumulative residual |
-0.6% (FADE) |
Stock has run +24% YTD to all-time highs pricing in a beat-and-raise, so even a solid Q2 (EPS/sales beat, modest FY raise) likely triggers only a muted pop on day 1. Because Q1's raise was already sizable and margin recovery (Innovative Medicine/MedTech) is only gradually reversing per management's own H1-loaded investment framing, the incremental FY raise this quarter is unlikely to match the magnitude of the quarterly beat - implying H2 buy-side numbers get trimmed at the margin even as headline Q2 prints clean. Combined with a stretched ~22x+ multiple after the rally, this sets up profit-taking/consolidation over the following days (sell-the-news fade) rather than continued follow-through, absent a much larger-than-expected guidance raise or ICOTYDE ramp surprise. |
LOW |